Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.
Following promising results in animal studies, Casodex (ICI 176,334) has been studied in the treatment of patients with advanced prostate cancer. At doses of 10, 30 and 50 mg, the drug was found to be well tolerated, with a moderate effect on sex hormone levels. The 50 mg dose of Casodex (daily) reduced previously elevated acid phosphatase levels by 50% or more in 71% of patients.
Lunglmayr
G
G
Department of Urology, Mistelbach General Infirmary, Austria.
D000135:Acid Phosphatase / Q000378:metabolism; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000813:Anilides / Q000008:administration & dosage / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D013739:Testosterone / Q000097:blood; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; D013739:Testosterone; D004958:Estradiol; D005640:Follicle Stimulating Hormone; C053541:bicalutamide; D000135:Acid Phosphatase